Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells $85,564.64 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 3,856 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $22.19, for a total transaction of $85,564.64. Following the transaction, the chief financial officer owned 107,080 shares in the company, valued at approximately $2,376,105.20. The trade was a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Tuesday, October 21st, Timothy Eugene Sullivan sold 10,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00.

Apellis Pharmaceuticals Trading Down 2.9%

Shares of NASDAQ APLS opened at $19.94 on Friday. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $31.17. The firm has a market capitalization of $2.52 billion, a P/E ratio of 64.32 and a beta of 0.31. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10. The company’s 50 day simple moving average is $22.89 and its 200 day simple moving average is $23.45.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.03 by $0.64. The company had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business’s revenue for the quarter was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.46) EPS. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on APLS. Weiss Ratings restated a “sell (d)” rating on shares of Apellis Pharmaceuticals in a report on Monday, December 29th. Cantor Fitzgerald cut their price target on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. Needham & Company LLC decreased their price objective on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Stifel Nicolaus lowered their target price on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Finally, HC Wainwright cut their target price on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Eleven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $33.65.

Apellis Pharmaceuticals News Summary

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterated a Buy on Apellis, signaling continued confidence in the company’s longer‑term commercial execution and pipeline upside — a supportive voice for holders focused beyond near‑term sales. Read More.
• Positive Sentiment: Stifel Nicolaus issued a Buy on APLS (or reiterated constructive coverage), adding a second favorable analyst view that could help stabilize valuation if execution improves. Read More.
• Neutral Sentiment: Analysts remain mixed on Apellis: some see upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued divergent research notes and volatile price reactions to company updates. Read More.
• Negative Sentiment: Apellis reported preliminary Q4 U.S. net product revenue of $190M and flagged weaker Syfovre sales with mixed Empaveli uptake — the main near‑term driver cited for a recent sharp weekly decline in the stock. Read More.
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) issued more pessimistic forecasts or lowered expectations, increasing downward pressure by reducing modeled revenues and price targets. Read More. Read More.
• Negative Sentiment: Significant insider selling on Jan. 13: multiple senior execs (CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others) sold shares at ~ $22.19 — filings show they still retain large stakes but the volume of disposals can be perceived negatively by the market. Read More.
• Negative Sentiment: Options flow indicated a large spike in put buying (reported >500% increase in put volume), reflecting elevated hedging and bearish positioning that can amplify short‑term volatility and downside pressure. Source: options flow reports

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently bought and sold shares of APLS. Corton Capital Inc. bought a new position in Apellis Pharmaceuticals during the 2nd quarter worth about $364,000. Simplify Asset Management Inc. acquired a new position in shares of Apellis Pharmaceuticals during the third quarter worth about $2,419,000. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Apellis Pharmaceuticals by 43.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock worth $1,838,000 after buying an additional 30,507 shares in the last quarter. Highland Capital Management LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at approximately $1,135,000. Finally, Schroder Investment Management Group lifted its stake in Apellis Pharmaceuticals by 91.9% in the 2nd quarter. Schroder Investment Management Group now owns 485,615 shares of the company’s stock valued at $8,406,000 after acquiring an additional 232,506 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.